以色列 - 希伯来文 - Ministry of Health

takeda israel ltd - brentuximab vedotin - אבקה להכנת תמיסה מרוכזת לעירוי - brentuximab vedotin 50 mg/vial - brentuximab vedotin

以色列 - 希伯来文 - Ministry of Health

roche pharmaceuticals (israel) ltd - polatuzumab vedotin - אבקה להכנת תמיסה מרוכזת לעירוי - polatuzumab vedotin 140 mg/vial

以色列 - 希伯来文 - Ministry of Health

astellas pharma international b.v., israel - enfortumab vedotin - אבקה להכנת תמיסה מרוכזת לעירוי - enfortumab vedotin 20 mg/vial - enfortumab vedotin

以色列 - 希伯来文 - Ministry of Health

astellas pharma international b.v., israel - enfortumab vedotin - אבקה להכנת תמיסה מרוכזת לעירוי - enfortumab vedotin 30 mg/vial - enfortumab vedotin

以色列 - 希伯来文 - Ministry of Health

וימטור בעמ - שיפור מראה העור

以色列 - 希伯来文 - Ministry of Health

roche pharmaceuticals (israel) ltd - methoxy polyethylene glycol-epoetin beta 250 mcg / 0.3 ml - solution for injection - methoxy polyethylene glycol-epoetin beta - treatment of anemia associated with chronic kidney disease (ckd).

以色列 - 希伯来文 - Ministry of Health

roche pharmaceuticals (israel) ltd - epoetin beta 2000 iu / 0.3 ml - solution for injection - erythropoietin - treatment of anemia associated with chronic renal failure (renal anemia) in patients on dialysis. treatment of symptomatic renal anemia in patients not yet undergoing dialysis. increasing the yield of autologous blood from patients in a pre-donation program. its use in this indication must be balanced against the reported increased risk of thromboembolic events. treatment should only be given to patients with moderate anemia (hb 10-13 g/dl (6.21- 8.07 mmol/l) no iron deficiency) or when blood conserving procedures are not available or insufficient when the scheduled major elective surgery requires a large volume of blood (4 or more units of blood for females or 5 or more units for males). treatment of anemia in adult patients with solid tumors and treated with platinum-based chemotherapy prone to induce anemia (cisplatin 75 mg/m2/cycle carboplatin: 350 mg/m2/cycle). treatment of anemia in adult patients with multiple myeloma low grade non-hodgkin's lymphoma or chronic lymphocytic leukemia who have a relative

以色列 - 希伯来文 - Ministry of Health

roche pharmaceuticals (israel) ltd - epoetin beta 3000 iu / 0.3 ml - solution for injection - erythropoietin - treatment of anemia associated with chronic renal failure (renal anemia) in patients on dialysis. treatment of symptomatic renal anemia in patients not yet undergoing dialysis. increasing the yield of autologous blood from patients in a pre-donation program. its use in this indication must be balanced against the reported increased risk of thromboembolic events. treatment should only be given to patients with moderate anemia (hb 10-13 g/dl (6.21- 8.07 mmol/l) no iron deficiency) or when blood conserving procedures are not available or insufficient when the scheduled major elective surgery requires a large volume of blood (4 or more units of blood for females or 5 or more units for males). treatment of anemia in adult patients with solid tumors and treated with platinum-based chemotherapy prone to induce anemia (cisplatin 75 mg/m2/cycle carboplatin: 350 mg/m2/cycle). treatment of anemia in adult patients with multiple myeloma low grade non-hodgkin's lymphoma or chronic lymphocytic leukemia who have a relative

以色列 - 希伯来文 - Ministry of Health

salomon,levin & elstein ltd - epoetin theta (r-huepo) 1000 iu / 0.5 ml - solution for injection - erythropoietin - - treatment of symptomatic anaemia associated with chronic renal failure in adult patients.- treatment of symptomatic anaemia in adult cancer patients with non-myeloid malignancies receiving chemotherapy.

以色列 - 希伯来文 - Ministry of Health

salomon,levin & elstein ltd - epoetin theta (r-huepo) 2000 iu / 0.5 ml - solution for injection - erythropoietin - - treatment of symptomatic anaemia associated with chronic renal failure in adult patients.- treatment of symptomatic anaemia in adult cancer patients with non-myeloid malignancies receiving chemotherapy.